Tiziana files patent on combination of NP-ACT D with anti-IL-6R
Category: #health  By Saipriya Iyer  Date: 2020-04-28
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Tiziana files patent on combination of NP-ACT D with anti-IL-6R

Tiziana Life Sciences, a biotechnology company, has recently announced the filing of a provisional patent application on a potential therapy for the COVID-19 disease. This potential therapy is the combination of NP-ACT D (nanoparticle-Actinomycin D) with anti-IL-6R (anti-interleukin-6 receptor monoclonal antibody).

The underlying concepts of the invention are based on the hypothesis that the combination of an anti-inflammatory agent, such as anti-IL-6R, that suppresses ‘Cytokine Storm’ with an antiviral drug that controls the proliferation of coronavirus may deliver immediate relief to severely infected COVID-19 patients.

ACT D (Actinomycin D), an antibiotic drug, is on the WHO’s List of Essential Medicines. However, severe complications and toxicities associated with the IV administration of this antibiotic drug limits its therapeutic utility. These severe toxicities may be overcome by NP-ACT D formulation. For instance, an animal study that compared NP-ACT D side-by-side with an equivalent dose of free ACT D resulted in 0% mortality among rats that were dosed with the NP-ACT D, where free ACT D dosed rats showed > 90% mortality. Nevertheless, the tolerability and safety of NP-ACT D are yet to be examined among healthy volunteers before advancing to the clinical studies.

Coronavirus-infected patients are known to develop cytokine storm, which is an uncontrolled immune response. It results in an excessive production of IL-6, TNF-a, and other inflammatory cytokines that potentially cause chronic inflammation. These cytokines are also believed to be linked with ARDS (acute respiratory distress syndrome) and severe lung damage in COVID-19 patients. Therefore, the company considers the potential combination of TZLS-501 and NP-ACT D to hinder viral proliferation and control lungs inflammation to reduce mediated lung damage & death of COVID-19 patients.

Tiziana has not conducted any pre-clinical or clinical research of NP-ACT D, either alone or by combining with anti-IL-6R to treat COVID-19 disease. However, it has established theoretical principals for drug combinations and is forming an assessment for the potential of the combination of research & anecdotal evidence that involves the activity of NP-ACT D on other coronavirus strands.

Source credit:

https://www.globenewswire.com/news-release/2020/04/27/2022531/0/en/Tiziana-Life-Sciences-Files-Patent-on-Combination-of-Nanoparticle-Actinomycin-D-with-Anti-Interleukin-6-Receptor-Monoclonal-Antibody-for-Treatment-of-Coronaviruses.html



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...